![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Kowarik, M. C.; Astling, D.; Lepennetier, G.; Ritchie, A.; Hemmer, B.; Owens, G. P. und Bennett, Jeffrey L.
(2021):
Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
In: Neurotherapeutics, Bd. 18, Nr. 1: S. 364-377
Richard, Yolande; Kemmerer, C. L.; Pernpeintner, V.; Ruschil, C.; Abdelhak, A.; Scholl, M.; Ziemann, U.; Krumbholz, M.; Hemmer, B. und Kowarik, M. C. 
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
Biberacher, V.; Schmidt, P.; Selter, R. C.; Pernpeintner, V.; Kowarik, M. C.; Buck, D.; Korn, T.; Berthele, A.; Kirschke, J.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2016):
Chasing the driver of fatigue in multiple sclerosis: brain MRI versus CSF.
In: Multiple Sclerosis Journal, Bd. 22: S. 31-32
[PDF, 71kB]